Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2018-02-14 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 3 -
Director's Dealing
2018-02-14 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-13 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated February 13, 2018. The content focuses on the entry into a material definitive agreement with Sarissa Capital Management LP, changes to the Board of Directors including appointment of new directors and departure of incumbent directors, and related compensatory arrangements. There is no financial data or earnings information, nor is it an annual or quarterly report. The primary subject is changes in the company's board and management structure. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 9131 characters, which is substantive and not a mere announcement or certification, supporting this classification.
2018-02-13 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 8, 2018, reporting the results of operations and financial condition for the quarter and full year ended December 31, 2017. It mentions a press release and a conference call regarding these results. The document itself is a current report (8-K) and does not contain the full financial statements or detailed financial data but rather announces the release of such information. The length is 3682 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, announcements of financial results or press releases furnished as exhibits in an 8-K are classified as Regulatory Filings (RNS) because they are announcements and not the full earnings release or interim report themselves. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-02-08 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.